Adverum Biotechnologies Inc (ADVM) Stock Price, Quote & News

Company Profile

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a f...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 656 9323

Fax: 650 649 1995

Website: adverum.com

Address:

100 Cardinal Way, Redwood City, United States

_Picsou Oct. 25 at 12:31 PM

$ADVM LLY doesn't have sufficient funds, you mean? lool...!! Or, perhaps ADVM doesn't need to boost its cash reserves... If it's the price paid that bothers you, the solution is simple... HOLD THIS STOCK...!!

0 · Reply

_Picsou Oct. 25 at 12:26 PM

$ADVM @TwongStocks ----------------------------------------------------------->

0 · Reply

_Picsou Oct. 25 at 12:23 PM

$ADVM @Dori13 YES! Lylli is powerful enough to conduct a very in-depth analysis of the potential of the companies it acquires. Here, the market for wet AMD is COLOSSAL (approximately $8 billion for the USA alone, if I'm not mistaken). A stock to DEFINITELY hold! See also my post here: ===> https://stocktwits.com/_Picsou/message/633699523

0 · Reply

_Picsou Oct. 25 at 12:17 PM

$ADVM Wouldn't these one-time genetic treatments, which allow the eye to produce its own aflibercept, a protein that helps reduce abnormal blood vessel growth and maintain vision, constitute a major, direct, and fairly imminent EXISTENTIAL threat to other therapies that work through regular injections (OTLK, and others)?

0 · Reply

TCzeck Oct. 25 at 4:52 AM

$ADVM This is funny, new news are companies downgrading the stock share price. Every stock in the last 4 months sky rocketed in share price after stock was downgraded per share price from news articles. Bring it on algorithm, I don't forget hirstory...

0 · Reply

Dori13 Oct. 24 at 8:31 PM

$ADVM anything that lilly buys is for a reason. So this stock must be valuable. I am keeping it!

1 · Reply

Rayportfolio Oct. 24 at 8:23 PM

$ADVM $ADTX great deal

0 · Reply

McLarkin Oct. 24 at 7:52 PM

$ADVM thats it, I'm out.. wierd deal and for others to vote on accepting. No money in bank means no leverage to get better... nobody counter offering. Still Lully bought me out of Verve too... so next will be better

0 · Reply

BiotechDrTrader Oct. 24 at 7:48 PM

$ADVM This buyout sucks

0 · Reply

resistancebreakers Oct. 24 at 7:39 PM

Update on $ADVM the buyer gets 3.56 upfront and will hold a CVR which will pay out extra totalling 12 per share, conditioned to 1 billion in sales. The stock has 8% short interest. 🪖🫡

1 · Reply

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

LLY

Oct 24, 2025, 10:11 AM EDT - 1 day ago

Eli Lilly to buy gene therapy developer Adverum in about $262 million deal

LLY

Oct 24, 2025, 8:30 AM EDT - 1 day ago

Lilly to Acquire Adverum Biotechnologies

LLY

Sep 22, 2025, 8:00 AM EDT - 4 weeks ago

Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration

Sep 5, 2025, 4:01 PM EDT - 7 weeks ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 12, 2025, 7:00 AM EDT - 2 months ago

Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights

Aug 6, 2025, 4:01 PM EDT - 2 months ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

May 14, 2025, 4:05 PM EDT - 5 months ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Apr 30, 2025, 10:00 AM EDT - 6 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation

Apr 28, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect

Apr 25, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation

Apr 24, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation

Apr 23, 2025, 10:00 AM EDT - 6 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 22, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Connect

Apr 20, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation

Apr 18, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out

Apr 17, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out

Apr 16, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect

Apr 15, 2025, 12:00 PM EDT - 6 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 15, 2025, 9:09 AM EDT - 6 months ago

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

Apr 4, 2025, 4:05 PM EDT - 7 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:01 PM EDT - 7 months ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 3, 2025, 4:01 PM EST - 8 months ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Feb 25, 2025, 7:00 AM EST - 8 months ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Feb 5, 2025, 4:05 PM EST - 9 months ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 20, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2024, 1:37 PM EST - 1 year ago

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 15, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Nov 4, 2024, 4:39 PM EST - 1 year ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jul 17, 2024, 3:35 PM EDT - 1 year ago

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Jul 17, 2024, 2:45 AM EDT - 1 year ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

May 9, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

May 3, 2024, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Feb 28, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 8, 2024, 7:00 AM EST - 1 year ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Feb 5, 2024, 7:45 AM EST - 1 year ago

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

_Picsou Oct. 25 at 12:31 PM

0 · Reply

_Picsou Oct. 25 at 12:26 PM

$ADVM @TwongStocks ----------------------------------------------------------->

0 · Reply

_Picsou Oct. 25 at 12:23 PM

0 · Reply

_Picsou Oct. 25 at 12:17 PM

0 · Reply

TCzeck Oct. 25 at 4:52 AM

0 · Reply

Dori13 Oct. 24 at 8:31 PM

$ADVM anything that lilly buys is for a reason. So this stock must be valuable. I am keeping it!

1 · Reply

Rayportfolio Oct. 24 at 8:23 PM

$ADVM $ADTX great deal

0 · Reply

McLarkin Oct. 24 at 7:52 PM

0 · Reply

BiotechDrTrader Oct. 24 at 7:48 PM

$ADVM This buyout sucks

0 · Reply

resistancebreakers Oct. 24 at 7:39 PM

Update on $ADVM the buyer gets 3.56 upfront and will hold a CVR which will pay out extra totalling 12 per share, conditioned to 1 billion in sales. The stock has 8% short interest. 🪖🫡

1 · Reply

resistancebreakers Oct. 24 at 6:54 PM

SHORT SQUEEZE call $LLY $ADVM it's gonna go MASSIVE 🔥🪖🫡☝️

1 · Reply

resistancebreakers Oct. 24 at 6:34 PM

$ADVM courtesy intel by our Spy Spion 🕵️‍♂️🪖🫡☝️

0 · Reply

BaroloBuff Oct. 24 at 6:34 PM

I had a massive position in $ADVM, as I believe in their technology, but they didn’t have the funds nor the competent management to bring this to approval alone, nor to get their shareholders a fair deal. Hopefully $CLSD we’ll have better luck with the acquisition/partner, I’m much better terms for us. I haven’t been here for a while as well.

1 · Reply

GABBYGIRL Oct. 24 at 6:23 PM

$ADVM this will fly at some point! A goid deal $12.47/

0 · Reply

TCzeck Oct. 24 at 5:55 PM

$ADVM Flatlined with approximate 1M+ shares traded per hour. That is a good sign! Reminds me of many stocks that flatline from great pre market news, then rise after hours by more than a few dollars per share... may not hapoen today, but it certainly will at some point.

0 · Reply

prismmarketview Oct. 24 at 5:42 PM

(NYSE: $LLY),(NASDAQ: $ADVM) #EliLillyandCo is acquiring #adverumbio in a deal valued up to $262M. The buyout includes $3.56 per share in cash plus contingent value rights worth up to $8.91 per share, tied to regulatory and commercial milestones for Ixo-vec, a one-time gene therapy for wet age-related macular degeneration (wAMD). The acquisition strengthens Lilly’s pipeline in eye disease and gene therapy, with the deal expected to close Q4 2025. https://prismmarketview.com/eli-lilly-expands-gene-therapy-footprint-with-262m-acquisition-of-adverum-biotechnologies/

0 · Reply

GABBYGIRL Oct. 24 at 5:16 PM

$ADVM $12.47 is the PRICE!

1 · Reply

EOD718 Oct. 24 at 4:57 PM

$ADVM they are investigating this , because the company is worth more than 3.56 it’s undervalued.. so keep shorting

0 · Reply

MrTicker Oct. 24 at 4:37 PM

$ADVM Eli Lilly (LLY) said earlier Friday it agreed to acquire Adverum Biotechnologies(ADVM) in a deal worth up to $12.47 per share. The purchase price includes $3.56 per share in cash payable at closing and an additional payment of up to $8.X.91 linked to the achievement of two milestones

1 · Reply

MrTicker Oct. 24 at 4:36 PM

$ADVM Mizuho has an outperform rating on Adverum Biotechnologies(ADVM) with a $12 price target

0 · Reply

MrTicker Oct. 24 at 4:35 PM

$ADVM Adverum Biotechnologies Buyout by Eli Lilly Represents 'Best Possible Outcome' for Company, Mizuho Says MT NEWSWIRES 11:33 AM ET 10/24/2025

0 · Reply

CouldBeTrueCouldBeFalse Oct. 24 at 4:02 PM

$ADVM buying this at $3 seems like good price atleast the .56 cent is guaranteed

0 · Reply

Market Cap	87.71M
Revenue (ttm)	1.00M
Net Income (ttm)	-130.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,093.00%
Debt to Equity Ratio	0.00

Volume	13,615,200
Avg Vol	644,120
Day's Range	N/A - N/A
Shares Out	20.98M
Stochastic %K	11%
Beta	0.98
Analysts	Strong Sell
Price Target	$19.50